Moderna stock’s 17% slump was a ‘sell the news’ event, analyst says

Moderna shares tumbled after leaked cancer vaccine trial data showed promising results for its treatment developed with Merck.

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.thestreet.com)